The preclinical study reported that the administration of GR-MD-02, which is a galectin-3 inhibitor, was able to reduce collagen fiber deposition in both the mouse NASH model and cirrhotic rats [32,33]. Here, LGALS3 is linked to metabolic dysfunction-associated steatohepatitis.